A carregar cotações...
Previsão
O preço-alvo médio dos analistas é € 19,18 (+96,32%). A mediana é € 17,77 (+81,88%).
| Comprar |
10 |
| Manter |
2 |
| Vender |
0 |
Notícias Ir para o feed de notícias
Immunic advances vidofludimus calcium toward Phase 3 readouts, expects data by year-end
Immunic said its Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing MS remain on track to deliver top-line data by the end of 2026, with a potential US NDA submission in mid-2027 and a regulatory decision targeted for 2028 if results are positive. The company plans to start a Phase 3 program in progressive MS later this year following supportive Phase 2 CALLIPER analyses. In Q2, operating expenses rose to $35.3 million and net loss widened to about $34.1 million; cash and equivalents totaled $155.1 million, which management expects to fund operations into late 2027. Immunic also strengthened its leadership and board ahead of potential commercialization. » Mais em finance.yahoo.com
Dados financeiros da empresa
| (EUR) | junho de 2026 | |
|---|---|---|
| Receitas | 0 | - |
| Ganho bruto | 0 | - |
| Ganho líquido | -29,88 mi | 31,30% |
| EBITDA | -29,79 mi | 31,13% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 134,85 mi |
Número de ações | 13,62 mi |
Máximo/mínimo de 52 semanas | € 15,11 - € 4,39 |
| Dividendos | Não |
Beta | 1,41 |
PER (PE Ratio) | -2,38 |
PEG (PEG Ratio) | -0,03 |
P/VC (PB Ratio) | 3,81 |
P/V (PS Ratio) | 0,00 |
Perfil da empresa
| Nome | Immunic |
| CEO | Erik Lundgren |
| Colaboradores | 100 |
